Skip to content

Project Intuition: Enabling Large-Scale Remote Cognitive Measurement with Apple and Biogen

product imagery - Rater Training

Industry

Digital Health

Challenge Summary

Cognitive health testing and research have historically relied on clinic-based testing, restricting reach, efficiency, and accessibility. The Intuition study aimed to develop scalable methods for identifying mild cognitive impairment (MCI) and tracking cognitive change using widely accessible consumer devices, across a broad and representative population in the US.

Solution Summary

Researchers integrated Cambridge Cognition’s CANTAB assessments into a custom research app for the iPhone and Apple Watch, enabling remote, repeatable cognitive testing alongside device and health data collection. This approach enabled large-scale, longitudinal cognitive monitoring using everyday technology.

Key Product

Cognitive Assessments

32%
underrepresented races/ethnicities
23k
participants enrolled
93%
assessment adherence
525k
high-frequency test sessions
picture of an office, with a few people working at desks

Biogen Inc

An American multinationalbiotechnology company based in Cambridge, Massachusetts, Biogen specializes in the discovery, development, and delivery of the treatment of neurological diseasesto patients worldwide. 

The Challenge

Earlier detection of cognitive decline allows earlier intervention, improving the chances of slowing progression and maintaining quality of life. However, brain health assessment has historically relied on clinic-based testing, restricting reach, efficiency, and accessibility.

The Intuition Brain Health Study aimed to evaluate whether consumer technology and digital cognitive assessments could enable cognitive health monitoring and detection of mild cognitive impairment (MCI) at scale, across a broad and representative population in the US.

Achieving this required a solution capable of delivering fully remote, high-frequency cognitive testing for tens of thousands of participants across diverse demographics, while generating reliable longitudinal data through multiple digital devices.

The Solution

Cambridge Cognition deployed a comprehensive solution, incorporating:

  • A targeted selection of their evidence-based digital cognitive assessments including:
    • Monthly desktop based cognitive evaluations
    • High-frequency smartphone-based tests within a custom study app
  • Multi-platform assessment delivery via Connect their cloud-based platform
  • A structured cohort design encompassing:
    • Early and middle adulthood controls
    • Late adulthood controls
    • Individuals reporting subjective cognitive complaints (SCC)
    • Participants with mild cognitive impairment (MCI)
“The use of Cambridge Cognition’s assessments in the Intuition study has shown promising results in remote detection of mild cognitive impairment, providing a scalable solution for tracking cognitive health.”
— Paul Monroe Butler, Lead Researcher  

Results

The study achieved:

Exceptional demographic representation:

  • 31.5% underrepresented racial and ethnic groups
  • 34.1% participants without a bachelor’s degree
  • 22.1% participants with annual income below $50,000
  • 64.4% female participants
  • Complete U.S. geographic coverage across all 50 states 

 Technical excellence:

  • Peak performance: 59 simultaneous assessments per minute
  • Industry-leading retention with only 10.5% attrition (vs. 49% industry average)
  • Robust data collection throughout 12-month duration

 Clinical validation:

  • Confirmed reliability of unsupervised cognitive testing
  • Documented expected age-related cognitive patterns
  • Distinguished cognitive performance variations among risk cohorts
  • Validated platform scalability and reliability

Study Details

Authors: Butler PM, Au R, Becker A, Bianchi MT, Brown R, Cosne G, et al.Title: "Intuition Brain Health Study: a smartphone- and smartwatch-based virtual, observational study using multimodal mobile sensing to classify and detect mild cognitive impairment"

Posted Date: March 29th, 2024

DOI: https://doi.org/10.21203/rs.3.rs-4173311/v1

Study Identifier: NCT05058950 (https://clinicaltrials.gov/study/NCT05058950)